Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Rating of “Buy” by Brokerages

Tyra Biosciences, Inc. (NASDAQ:TYRA) has been given an average rating of “Buy” by the six research firms that are currently covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 12 month target price among analysts that have covered the stock in the last year is $30.50.

TYRA has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Tyra Biosciences in a research report on Tuesday, February 18th. UBS Group assumed coverage on Tyra Biosciences in a research report on Tuesday, January 7th. They set a “buy” rating and a $28.00 target price on the stock.

Insider Buying and Selling

In related news, Director Nina S. Kjellson sold 3,993 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $16.36, for a total value of $65,325.48. Following the sale, the director now owns 3,707,420 shares in the company, valued at $60,653,391.20. This represents a 0.11 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have sold a total of 21,998 shares of company stock worth $344,818 in the last quarter. Company insiders own 15.40% of the company’s stock.

Institutional Investors Weigh In On Tyra Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of TYRA. Alta Partners Management Company L.P. acquired a new stake in shares of Tyra Biosciences in the 4th quarter worth approximately $56,716,000. Boxer Capital Management LLC purchased a new stake in Tyra Biosciences in the 4th quarter valued at approximately $28,185,000. Janus Henderson Group PLC purchased a new stake in Tyra Biosciences in the 3rd quarter valued at approximately $24,994,000. Farallon Capital Management LLC purchased a new stake in Tyra Biosciences in the 4th quarter valued at approximately $13,914,000. Finally, Vestal Point Capital LP purchased a new stake in Tyra Biosciences in the 4th quarter valued at approximately $13,761,000. Institutional investors and hedge funds own 84.14% of the company’s stock.

Tyra Biosciences Stock Performance

Tyra Biosciences stock opened at $12.03 on Wednesday. Tyra Biosciences has a fifty-two week low of $11.89 and a fifty-two week high of $29.60. The company has a market capitalization of $608.72 million, a P/E ratio of -7.47 and a beta of 1.05. The stock has a 50-day simple moving average of $14.37 and a 200-day simple moving average of $18.05.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.